199 related articles for article (PubMed ID: 18468987)
1. Measuring specific, rather than generalized, cognitive deficits and maximizing between-group effect size in studies of cognition and cognitive change.
Silverstein SM
Schizophr Bull; 2008 Jul; 34(4):645-55. PubMed ID: 18468987
[TBL] [Abstract][Full Text] [Related]
2. Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.
Barch DM; Carter CS;
Schizophr Bull; 2008 Jul; 34(4):613-8. PubMed ID: 18499705
[TBL] [Abstract][Full Text] [Related]
3. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
4. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
Keefe RS; Harvey PD
Schizophr Bull; 2008 Jul; 34(4):656-63. PubMed ID: 18495645
[TBL] [Abstract][Full Text] [Related]
5. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
6. The translation of cognitive paradigms for patient research.
Luck SJ; Gold JM
Schizophr Bull; 2008 Jul; 34(4):629-44. PubMed ID: 18487226
[TBL] [Abstract][Full Text] [Related]
7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
8. Building a clinically relevant cognitive task: case study of the AX paradigm.
MacDonald AW
Schizophr Bull; 2008 Jul; 34(4):619-28. PubMed ID: 18487225
[TBL] [Abstract][Full Text] [Related]
9. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Keefe RS; Goldberg TE; Harvey PD; Gold JM; Poe MP; Coughenour L
Schizophr Res; 2004 Jun; 68(2-3):283-97. PubMed ID: 15099610
[TBL] [Abstract][Full Text] [Related]
10. The neuropsychological signature of schizophrenia: generalized or differential deficit?
Blanchard JJ; Neale JM
Am J Psychiatry; 1994 Jan; 151(1):40-8. PubMed ID: 8267133
[TBL] [Abstract][Full Text] [Related]
11. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
Keefe RS; Poe M; Walker TM; Kang JW; Harvey PD
Am J Psychiatry; 2006 Mar; 163(3):426-32. PubMed ID: 16513863
[TBL] [Abstract][Full Text] [Related]
12. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
Buchanan RW
Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
[No Abstract] [Full Text] [Related]
13. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
14. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
15. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
Bromley E
Psychiatr Serv; 2007 Apr; 58(4):475-81. PubMed ID: 17412848
[TBL] [Abstract][Full Text] [Related]
16. Screening of Cognitive Impairment in Schizophrenia: Reliability, Sensitivity, and Specificity of the Repeatable Battery for the Assessment of Neuropsychological Status in a Spanish Sample.
De la Torre GG; Perez MJ; Ramallo MA; Randolph C; González-Villegas MB
Assessment; 2016 Apr; 23(2):221-31. PubMed ID: 25934161
[TBL] [Abstract][Full Text] [Related]
17. [Measuring impairment of facial affects recognition in schizophrenia. Preliminary study of the facial emotions recognition task (TREF)].
Gaudelus B; Virgile J; Peyroux E; Leleu A; Baudouin JY; Franck N
Encephale; 2015 Jun; 41(3):251-9. PubMed ID: 25240938
[TBL] [Abstract][Full Text] [Related]
18. [MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia].
Jedrasik-Styła M; Ciołkiewicz A; Denisiuk M; Linke M; Parnowska D; Gruszka A; Jarema M; Wichniak A
Psychiatr Pol; 2012; 46(2):261-71. PubMed ID: 23214396
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
20. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
[Next] [New Search]
